e1fbf667f2af74da62a357c9bb6119e5fffe5243
Home.md
| ... | ... | @@ -10,19 +10,6 @@ This site tracks all genes that have been nominated as recurrently mutated in on |
| 10 | 10 | |
| 11 | 11 | To get started, select one of the gene lists from the table below then select the `gene page` link for any gene in the table or explore the genes nominated by [individual studies](Papers). |
| 12 | 12 | |
| 13 | -## Categorization |
|
| 14 | - |
|
| 15 | -### Gene Tiers |
|
| 16 | - |
|
| 17 | -**Tier 2** - Any gene described as significantly or recurrently mutated in one or more types of B-cell lymphoma is initially assigned to Tier 2 for that entity. The study describing the mutation of that gene in a particular entity is considered the originating study. |
|
| 18 | - |
|
| 19 | -**Tier 1** - Genes can transition to Tier 1 only after additional studies have demonstrated the recurrence of mutations in the same entity. |
|
| 20 | - |
|
| 21 | -### Gene Designations |
|
| 22 | - |
|
| 23 | -**aSHM** - Denotes genes as affected by aberrant somatic hypermutation (aSHM). Tier 1 and Tier 2 genes can have this designation, respectively abbreviated as *1-a* and *2-a*. For example, see [BCL7A](BCL7A). |
|
| 24 | - |
|
| 25 | -**Fail** - Some studies with large additions to Tier 2 lists have undergone manual review of the primary data. If the majority of mutations in a gene fail QC, the gene will be given the designation *2-F*. For example, see [MARK1](MARK1). |
|
| 26 | 13 | |
| 27 | 14 | ```mermaid |
| 28 | 15 | --- |
| ... | ... | @@ -196,6 +183,21 @@ MCL-exome, Zhang 2014, 28 |
| 196 | 183 | |[@paneaWholeGenomeLandscape2019](papers/paneaWholeGenomeLandscape2019)|BL|4|22 (55%)| |
| 197 | 184 | |[@hubschmannMutationalMechanismsShaping2021b](papers/hubschmannMutationalMechanismsShaping2021b)|DLBCL,FL|4|TBD| |
| 198 | 185 | |
| 186 | +## Categorization |
|
| 187 | + |
|
| 188 | +### Gene Tiers |
|
| 189 | + |
|
| 190 | +**Tier 2** - Any gene described as significantly or recurrently mutated in one or more types of B-cell lymphoma is initially assigned to Tier 2 for that entity. The study describing the mutation of that gene in a particular entity is considered the originating study. |
|
| 191 | + |
|
| 192 | +**Tier 1** - Genes can transition to Tier 1 only after additional studies have demonstrated the recurrence of mutations in the same entity. |
|
| 193 | + |
|
| 194 | +### Gene Designations |
|
| 195 | + |
|
| 196 | +**aSHM** - Denotes genes as affected by aberrant somatic hypermutation (aSHM). Tier 1 and Tier 2 genes can have this designation, respectively abbreviated as *1-a* and *2-a*. For example, see [BCL7A](BCL7A). |
|
| 197 | + |
|
| 198 | +**Fail** - Some studies with large additions to Tier 2 lists have undergone manual review of the primary data. If the majority of mutations in a gene fail QC, the gene will be given the designation *2-F*. For example, see [MARK1](MARK1). |
|
| 199 | + |
|
| 200 | + |
|
| 199 | 201 | ## B-cell lymphoma mutation browser |
| 200 | 202 | |
| 201 | 203 |  |